Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Afrezza Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.01.83

    Afrezza (insulin human inhalation powder) Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.01.83 alerts

    Get alerted when Policy 05.01.83 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity determinations for Afrezza for members with type 1 or type 2 diabetes mellitus, including clinical eligibility, required documentation, preferred-therapy prerequisites, approval duration, exclusions, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyAfrezza (insulin human inhalation powder) Coverage Criteria
    Policy CodePolicy 05.01.83
    Change TypeNo material change
    Effective DateOctober 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit pulmonary function testing before initial approval and repeat it with each renewal.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 6+Minimum age for covered use
    12 monthsApproval duration
    3 monthsMinimum stable maintenance period
    2–6 boxesMaximum 30-day quantities

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Asthma/COPD; smokingCoverage exclusions

    Medical Necessity and Coverage Criteria

    Initial and Renewal Medical-Necessity Pathways

    Afrezza may be considered medically necessary when any one of the following complete pathways is met:

    Covered pathways

    • Stable-dose and response pathway

      • No pulmonary or smoking exclusion: The patient does not have chronic lung disease such as asthma or COPD and does not currently smoke or have recently stopped smoking within the past 6 months.No smoking or smoking cessation within the past 6 months
      • Pulmonary evaluation: The patient has been evaluated with pulmonary function tests to rule out bronchospasm or chronic lung disease.Before initial approval and with each renewal
      • Stable treatment: The patient has been receiving a stable maintenance dose of Afrezza.At least 3 months
      • Clinical response: The patient has demonstrated a reduction in hemoglobin A1c since starting Afrezza.Reduction in HbA1c
    • Type 1 diabetes pathway

      • Age and diagnosis: The patient is 6 years or older and has type 1 diabetes mellitus.Age >= 6 years
      • Preferred insulin issue: The patient has experienced intolerance or has a contraindication to preferred injectable rapid-acting insulins.Documented intolerance or contraindication
      • Combination therapy: Afrezza will be used in combination with long-acting insulin.Concurrent long-acting insulin
    • Type 2 diabetes pathway

      • Age and diagnosis: The patient is 6 years or older and has type 2 diabetes mellitus.Age >= 6 years
      • Preferred insulin issue: The patient has experienced intolerance or has a contraindication to preferred injectable rapid-acting insulins.Documented intolerance or contraindication
      • Other antidiabetic therapy: The patient has experienced an inadequate treatment response, intolerance, or a contraindication to metformin and another non-insulin antidiabetic agent.Metformin and another non-insulin antidiabetic agent

        Both therapies are required.

    Coverage is excluded for patients with chronic lung disease, including asthma or chronic obstructive pulmonary disease (COPD). Afrezza is also not recommended for patients who currently smoke or who have stopped smoking within the past 6 months.

    Injection-site fatigue and workplace safety concerns do not qualify as an intolerance or contraindication to subcutaneous rapid-acting insulin and therefore do not support Afrezza approval on that basis.

    Afrezza is considered not medically necessary when the patient does not meet the policy's coverage criteria.

    Key Coverage Parameters

    Minimum age
    Minimum age6 years or older
    Type 1 diabetesCovered use applies to patients 6 years or older with type 1 diabetes mellitus
    Type 2 diabetesCovered use applies to patients 6 years or older with type 2 diabetes mellitus
    Stable maintenance therapy
    Required durationAt least 3 months
    Therapy statusThe patient must be receiving a stable maintenance dose of Afrezza
    Associated responseThe patient must demonstrate a reduction in hemoglobin A1c since starting therapy

    Authorization and Documentation Requirements

    Prior Authorization

    Document One Covered Clinical Pathway

    Submit documentation showing that the patient meets one covered clinical pathway for Afrezza prior authorization. Afrezza may be considered for an eligible patient with type 1 or type 2 diabetes who meets the applicable requirements below.

    • Pathway 1: No chronic lung disease such as asthma or COPD, does not currently smoke or have a smoking cessation history within the past 6 months, has required pulmonary function testing, has received a stable Afrezza maintenance dose for at least 3 months, and has demonstrated a reduction in HbA1c since starting therapy.
    • Pathway 2: Patient is at least 6 years old with type 1 diabetes, has intolerance or a contraindication to preferred injectable rapid-acting insulin, and will use Afrezza in combination with long-acting insulin.
    • Pathway 3: Patient is at least 6 years old with type 2 diabetes, has intolerance or a contraindication to preferred injectable rapid-acting insulin, and has had an inadequate response, intolerance, or contraindication to metformin and another non-insulin antidiabetic agent.
    Prior Authorization

    12-Month Approval Duration

    If approved, Afrezza authorization is granted for 12 months.

    Policy and Product Background

    Afrezza is a rapid-acting inhaled insulin indicated to improve glycemic control in eligible patients 6 years of age and older with type 1 or type 2 diabetes mellitus. In patients with type 1 diabetes, Afrezza is not a substitute for long-acting insulin and must be used in combination with it.

    Definitions

    Afrezza
    ProductAfrezza (insulin human inhalation powder)
    Drug classRapid-acting inhaled insulin
    IndicationUsed to improve glycemic control in patients 6 years of age and older with type 1 or type 2 diabetes mellitus
    Pulmonary function tests
    PurposeTest-based evaluation to rule out bronchospasm or chronic lung disease
    Initial approvalRequired prior to initial approval
    RenewalMust be repeated with each renewal

    Initial Approval Criteria

    Initial Approval

    Initial approval requires pulmonary function testing before approval and satisfaction of at least one of the following complete clinical pathways:

    Initial approval requirements

    • Covered clinical pathway

      • Stable-dose and response pathway: The patient has no chronic lung disease or disqualifying smoking history, has completed pulmonary function testing, has received a stable Afrezza maintenance dose for at least 3 months, and has demonstrated a reduction in HbA1c since initiation.Stable dose at least 3 months; reduced HbA1c
      • Type 1 diabetes pathway: The patient is 6 years or older with type 1 diabetes, has intolerance or a contraindication to preferred injectable rapid-acting insulin, and will use Afrezza in combination with long-acting insulin.Age 6 years or older

    Continuation and Renewal Criteria

    Continuation and Renewal

    Renewal requires repeat pulmonary function testing and continued satisfaction of the applicable medical-necessity pathway:

    Renewal requirements

    • Repeat pulmonary evaluation: Repeat pulmonary function testing to rule out bronchospasm or chronic lung disease.With each renewal
    • Applicable clinical pathway

      • Stable-dose and response pathway: The patient continues to have no chronic lung disease or disqualifying smoking history, has a stable Afrezza maintenance dose for at least 3 months, and has demonstrated a reduction in HbA1c since starting therapy.Stable dose at least 3 months; reduced HbA1c

    Preferred Therapy Requirements

    StepRequired therapy before AfrezzaAdditional requirements
    1Use cost-effective oral antidiabetic agents and/or preferred rapid-acting insulin products before Afrezza when clinically appropriate.For type 1 diabetes: document intolerance or contraindication to preferred injectable rapid-acting insulins. For type 2 diabetes: also document inadequate response, intolerance, or contraindication to metformin and another non-insulin antidiabetic agent.

    Afrezza Quantity Limits

    Afrezza 4/8 unit combo package
    PackageAfrezza 4/8 unit combo package: 90 cartridges of 4 units and 90 cartridges of 8 units
    Maximum boxes3 boxes per 30 days
    Maximum quantity3,240 units per 30 days
    Afrezza 8/12 unit combo package
    PackageAfrezza 8/12 unit combo package: 90 cartridges of 8 units and 90 cartridges of 12 units
    Maximum boxes2 boxes per 30 days
    Maximum quantity3,600 units per 30 days
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyAfrezza (insulin human inhalation powder) Coverage Criteria
    Policy CodePolicy 05.01.83
    Change TypeNo material change
    Effective DateOctober 3, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit pulmonary function testing before initial approval and repeat it with each renewal.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaKey Coverage ParametersAuthorization and Documentation RequirementsPolicy and Product BackgroundDefinitionsInitial Approval CriteriaContinuation and Renewal CriteriaPreferred Therapy RequirementsAfrezza Quantity Limits
    Smoking cessation interval
    Current smokingAfrezza is not recommended for patients who smoke
    Cessation intervalNo smoking cessation within the past 6 months
    Recent smoking cessationPatients who have recently stopped smoking are excluded from this coverage pathway
    Approval duration
    Approval duration12 months
    Authorization statusIf approved, authorization will be granted for 12 months
    Policy approval termApproval will be for 12 months
    • Submit required clinical documentation for each renewal before the authorization expires.
    Step Therapy

    Complete Preferred-Therapy Prerequisites

    Document that cost-effective oral antidiabetic agents and/or preferred rapid-acting insulin products have been used before Afrezza when applicable.

    • For type 1 diabetes, address intolerance or contraindication to preferred injectable rapid-acting insulins.
    • For type 2 diabetes, document inadequate response, intolerance, or contraindication to metformin and another non-insulin antidiabetic agent, as well as intolerance or contraindication to preferred injectable rapid-acting insulin.
    • Injection-site fatigue and workplace safety concerns do not establish intolerance or contraindication to subcutaneous rapid-acting insulin.
    Documentation Required

    Pulmonary Function Testing Required

    Submit pulmonary function testing before initial approval to rule out bronchospasm or chronic lung disease, and repeat the testing with each renewal as required.

    • Testing should support that Afrezza can be used safely and that the patient does not have a contraindicating chronic lung condition such as asthma or COPD.
    Documentation Required

    Document Treatment Response

    For continuation of therapy, document that the patient has received a stable Afrezza maintenance dose for at least 3 months and has demonstrated a reduction in HbA1c since starting treatment.

    • Include the relevant treatment duration, maintenance dose, and HbA1c values or clinical records demonstrating response.
    Documentation Required

    Document Alternative-Therapy History

    For type 1 diabetes, document intolerance or a contraindication to preferred injectable rapid-acting insulins and confirm that Afrezza will be used with long-acting insulin.

    • The patient must be at least 6 years old.
    • Afrezza must be used in combination with long-acting insulin; it cannot replace basal insulin.
    Denial Risk

    Avoid Clinical or Criteria Failure

    Coverage is not medically necessary when the patient has a contraindicating condition, an excluded smoking history, or otherwise fails to meet the applicable criteria.

    • Do not request Afrezza for a patient with chronic lung disease such as asthma or COPD because of the risk of acute bronchospasm.
    • Do not request Afrezza for a patient who currently smokes or stopped smoking within the past 6 months; safety and efficacy in these patients have not been established.
    • Document the required pulmonary function testing, stable therapy, HbA1c response, and applicable treatment history. Patients who do not meet the stated criteria are not medically necessary for coverage.
    Denial Risk

    Use Afrezza Only for Appropriate Indications

    Afrezza is a rapid-acting inhaled insulin and must not be used as a substitute for long-acting insulin in type 1 diabetes or for treatment of diabetic ketoacidosis.

    • In type 1 diabetes, use Afrezza only in combination with long-acting insulin.
    • Afrezza is not recommended for diabetic ketoacidosis.
    • Do not treat injection-site fatigue or workplace safety concerns alone as an approvable intolerance or contraindication to injectable rapid-acting insulin.
  1. Type 2 diabetes pathway: The patient is 6 years or older with type 2 diabetes, has intolerance or a contraindication to preferred injectable rapid-acting insulin, and has experienced an inadequate treatment response, intolerance, or contraindication to metformin and another non-insulin antidiabetic agent.Age 6 years or older
  2. Pulmonary function testing: The patient has been evaluated with pulmonary function tests to rule out bronchospasm or chronic lung disease.Before initial approval
  3. Type 1 diabetes pathway: The patient continues to be 6 years or older with type 1 diabetes, has intolerance or a contraindication to preferred injectable rapid-acting insulin, and uses Afrezza in combination with long-acting insulin.Age 6 years or older
  4. Type 2 diabetes pathway: The patient continues to be 6 years or older with type 2 diabetes, has intolerance or a contraindication to preferred injectable rapid-acting insulin, and has experienced an inadequate treatment response, intolerance, or contraindication to metformin and another non-insulin antidiabetic agent.Age 6 years or older
  5. Afrezza 4-unit cartridges
    PackageAfrezza 4-unit cartridges, 90 cartridges per box
    Maximum boxes6 boxes per 30 days
    Maximum quantity2,160 units per 30 days
    Afrezza 8-unit cartridges
    PackageAfrezza 8-unit cartridges, 90 cartridges per box
    Maximum boxes5 boxes per 30 days
    Maximum quantity3,600 units per 30 days
    Afrezza 12-unit cartridges
    PackageAfrezza 12-unit cartridges, 90 cartridges per box
    Maximum boxes3 boxes per 30 days
    Maximum quantity3,240 units per 30 days